AI
PMVP icon

Acuitas Investments’s PMV Pharmaceuticals PMVP Stock Holding History

Acuitas Investments’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-440,687
Closed -$657K – 106
2024
Q3 		$657K Buy
440,687
+86,938
+25% +$134K 0.29% 95
2024
Q2 		$573K Buy
353,749
+1,874
+0.5% +$3.38K 0.31% 91
2024
Q1 		$598K Buy
+351,875
New +$657K 0.3% 94

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuitas Investments's PMVP Position: Q4 2024 in Review

Acuitas Investments sold out of PMV Pharmaceuticals (PMVP) in Q4 2024, closing a stake of 440,687 shares — an estimated $657K sold.

Acuitas Investments first reported a position in PMVP in Q1 2024 and held it in 3 quarters. The position peaked at $657K in Q3 2024. 70 funds tracked by Wall St. Rank hold PMVP as of Q4 2024.

  • Acuitas Investments reported no remaining PMV Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 440,687 PMV Pharmaceuticals shares in Q4 2024, an estimated $657K.
  • Acuitas Investments first reported a position in PMV Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Acuitas Investments's PMV Pharmaceuticals position peaked at $657K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.